We have treated only eight patients with allopurinol, selected because their hyperuricaemia and gout were uncontrollable by standard measures, and because they were prepared for detailed and prolonged study. In view of the theoretical possibility that inhibition of xanthine oxidase might also have an effect in iron metabolism (Green and Mazur, 1957; Mazur, Green, Saha, and Carleton, 1958; Mazur and Carleton, 1965) and the increase in the hepatic content of iron in rats given allopurinol (Powell and Emmerson, 1966) , we were especially interested in any effects which allopurinol might have on iron metabolism or on haemopoiesis in these patients.
The first aspect of interest concerns the reticulocyte counts ( Fig. 1) In view of this reticulocytosis, the next aspect which was investigated was the red cell survival time, measured by the "1chromium labelling technique (Veall and Vetter, 1958) . The results in relation to months of allopurinol therapy are shown in Fig. 2 (Fig. 3) . In most patients, allowing for the wide fluctuations known to occur in the serum iron concentration from day to day and week to week, the serum iron concentrations obtained were probably not abnormal. Some This patient has severe hyperlipaemia and coronary artery disease and was receiving anticoagulants both before and since allopurinol was commenced. From 6 months after allopurinol therapy was begun, he has also been receiving chlorphenoxyisobutyrate ("Atromid"). Though there is no recognized effect of this drug on iron metabolism, its use does introduce a complicating factor in assessing the significance of his serum iron concentrations. The patient also had a high serum iron-binding capacity of448 ,ug./100 ml. at a time when the serum iron was 210 ,ug./100 ml.
In summarizing this aspect in these patients, therefore, the serum iron concentrations have been within the normal range except for isolated readings. The one patient with a consistently high serum iron concentration demonstrates an unusual fluctuation in these levels and is also receiving other drugs.
Because of difficulty in interpreting the significance of these serum iron results, a test of the extent of iron stores was undertaken using a chelating agent; we (Fig. 4) . It may be seen that, in general, the iron excretion after DTPA tends to rise with increasing duration of allopurinol treatment. The values of 0 24 and 0 27 (shown by 6 and (), although within the normal range, would rarely occur in a group of eight subjects within the normal population, and were regarded with suspicion. The patient with the persistently high serum iron (I) had a very low iron excretion after DTPA. One month later, the iron excretions after DTPA were repeated in three of the patients, the second result being joined to the first by a line. None had fallen and one (() had risen beyond the normal range.
In view of this finding, and after full discussion with the patients involved, liver biopsies were carried out on the two patients (0 and 9) with the highest DTPA-induced iron excretions. However, iron deposition in the liver using specific iron stains was not increased beyond that which would be found in the normal Brisbane population. Thus, in patients treated with allopurinol for up to 20 months, we found no unequivocal evidence of increased iron storage. However, as 20 months is a relatively short period in the life span of man and as it is possible that iron deposition may take even longer than this to develop, it seems reasonable to continue observation of the serum iron concentration and of the DTPA-induced iron excretion in patients on prolonged allopurinol therapy. However, it is clear that the slower the deposition, the less significant does any iron accumulation become.
In 
